ID1 Antibody

What is ID1 protein and why is it important in cellular research?

ID1 (Inhibitor of DNA binding 1) is a dominant-negative inhibitor of basic helix-loop-helix (bHLH) transcription factors. The protein lacks the basic DNA binding domain and antagonizes the transcriptional activity of many differentiation-specific bHLH transcription factors by forming DNA binding-incompetent heterodimers . ID1 plays critical roles in cellular processes including suppression of cellular senescence, facilitation of immortalization through p16 INK4A repression, and interference with the Rb regulatory pathway . Its importance in research stems from its overexpression in multiple human cancers and immortalized cells, making it a valuable target for studying cancer progression and cellular immortalization mechanisms .

What cell types and tissues commonly express ID1?

ID1 expression has been detected in various cell types including human embryonic stem cells, cancer cell lines (HepG2, MCF-7, PC-3), and nasopharyngeal epithelial cells . It has also been identified in early B lymphopoiesis cells where it restrains developmental progression . In terms of subcellular localization, ID1 demonstrates both nuclear and cytoplasmic expression patterns, with approximately 80% of positive cells showing prominent cytoplasmic staining in breast carcinoma samples . The ID1 marker can also be used to identify Type 1 Descending Thin Limb Cells in kidney tissue .

How do I optimize ID1 antibody concentration for Western blotting?

For optimal Western blot results with ID1 antibody, the concentration should be determined through titration experiments for each specific application and sample type. Based on published protocols, a starting concentration of 1 μg/mL is recommended when using goat anti-human/mouse ID1 antigen affinity-purified polyclonal antibody for detecting ID1 in cell line lysates with 20 μg of cytoplasmic protein or 10 μg of nuclear extracts . For other applications, concentrations may vary: 1:1000 dilution for Santa Cruz Biotechnology ID1 antibody has been reported effective for 25 μg of protein lysates . To determine the optimal concentration, perform a dilution series (e.g., 0.5 μg/mL, 1 μg/mL, 2 μg/mL) and select the concentration that provides the strongest specific signal with minimal background.

What are the best positive and negative control cell lines for ID1 antibody validation?

Based on research data, recommended positive control cell lines for ID1 antibody validation include:

• PC-3 (human prostate cancer cells): Shows strong ID1 expression

• HepG2 (human hepatocellular carcinoma): Demonstrates detectable ID1 levels

• MCF-7 (human breast cancer cells): Expresses ID1 protein

Effective negative control cell lines include:

• Daudi (human Burkitt's lymphoma cells): Reported to lack ID1 expression

When using these controls, it's important to validate both the presence of the specific ID1 band at approximately 25 kDa in positive controls and its absence in negative controls . This validation approach helps confirm antibody specificity before proceeding with experimental samples.

What are the recommended protocols for detecting ID1 using immunofluorescence?

For optimal immunofluorescence detection of ID1, follow this methodological approach:

• Fix cells using immersion fixation (4% paraformaldehyde for 15 minutes at room temperature)

• Permeabilize with 0.1% Triton X-100 in PBS for 10 minutes

• Block with 1-5% BSA or normal serum from the same species as the secondary antibody

• Incubate with ID1 primary antibody at 5-10 μg/mL for 3 hours at room temperature

• Wash thoroughly with PBS (3 times, 5 minutes each)

• Apply fluorescent-conjugated secondary antibody (e.g., NorthernLights™ 557-conjugated Anti-Goat IgG)

• Counterstain nuclei with DAPI

• Mount and visualize using fluorescence microscopy

This protocol has been validated in multiple cell types including PC-3, BG01V human embryonic stem cells, and differentiated neural progenitor cells . ID1 staining typically localizes to both nuclei and cytoplasm, with the pattern varying depending on cell type and differentiation status. For quantitative analysis, include appropriate positive controls (PC-3 cells) and negative controls (Daudi cells) to validate staining specificity .

How can I distinguish between specific and non-specific bands when performing Western blot for ID1?

To distinguish between specific and non-specific bands when detecting ID1 by Western blotting:

• Molecular weight identification: The specific ID1 band should appear at approximately 25 kDa . Any bands significantly deviating from this size might represent non-specific binding.

• Positive and negative controls: Include validated positive controls (HepG2, MCF-7, PC-3 cells) and negative controls (Daudi cells) to confirm the specific ID1 band .

• Subcellular fractionation: Prepare separate cytoplasmic and nuclear extracts, as ID1 is present in both compartments. This approach helps identify the authentic ID1 signal based on its known subcellular distribution patterns .

• Blocking optimization: Use 5% non-fat dry milk or BSA in TBST for blocking, and ensure the antibody diluent contains 1-3% of the blocking agent to minimize non-specific binding.

• Secondary antibody controls: Include a lane with no primary antibody but with secondary antibody to identify any bands resulting from non-specific secondary antibody binding.

• Antibody validation: Consider using siRNA knockdown of ID1 or overexpression systems to confirm band specificity through the expected decrease or increase in signal intensity.

What experimental approaches can detect the interaction between ID1 and other proteins?

Several experimental approaches can effectively detect ID1 protein interactions:

• Co-immunoprecipitation (Co-IP): This is the gold standard for detecting protein-protein interactions. For ID1, prepare 150 μg of cell lysates and immunoprecipitate using flag-tagged, Aurora A, or cdh1 antibodies recovered on protein A/G agarose beads (4 hours at 4°C). The immunoprecipitated complexes can then be analyzed by Western blotting using specific antibodies against ID1 or its potential binding partners .

• Proximity Ligation Assay (PLA): This technique allows visualization of protein interactions in situ with high sensitivity. Use antibodies against ID1 and its potential interacting proteins from different species, followed by species-specific PLA probes.

• Bimolecular Fluorescence Complementation (BiFC): This approach involves tagging ID1 and potential binding partners with complementary fragments of a fluorescent protein. When the proteins interact, the fragments come together to form a functional fluorophore.

• GST pull-down assays: Express ID1 as a GST-fusion protein, purify it using glutathione-agarose beads, and incubate with cell lysates containing potential binding partners. Analyze bound proteins by Western blotting.

• FRET (Fluorescence Resonance Energy Transfer): Tag ID1 and its potential binding partner with compatible fluorophores and measure energy transfer as evidence of close proximity indicative of interaction.

Based on published research, ID1 has been shown to interact with Aurora A and cdh1 using co-immunoprecipitation methods, revealing its role in mitotic regulation .

How does ID1 expression correlate with tumor grade in breast cancer tissue?

ID1 expression shows a strong positive correlation with breast cancer progression, making it both a valuable biomarker and potential therapeutic target. Research has demonstrated a clear relationship between ID1 expression levels and tumor grade in breast carcinoma samples:

• Grade I invasive carcinoma: Approximately 20% of biopsies show strong ID1 staining

• Grade III invasive carcinoma: More than 60% of samples exhibit strong ID1 expression

This significant increase in ID1 expression with higher tumor grade suggests its involvement in breast cancer progression and aggression. Methodologically, this correlation was established through immunohistochemistry, Western blotting, and in situ hybridization techniques . The predominant cytoplasmic staining pattern (observed in approximately 80% of ID1-positive cells) may serve as an additional diagnostic feature. These findings validate ID1 not only as a prognostic marker but also as a potential therapeutic target, particularly for aggressive breast carcinomas that frequently overexpress this protein .

What methods can be used to study the effects of ID1 knockdown or overexpression in cell models?

To investigate the functional consequences of altered ID1 expression:

For ID1 overexpression:

• Retroviral transduction: Subclone full-length human ID1 gene into a retroviral construct (e.g., pBabe-puro), transfect into packaging cells (e.g., PT67), and use viral supernatant to infect target cells. Select stable transformants using puromycin (0.8 μg/ml for 14 days) .

• Transient transfection: Use expression plasmids containing flag-tagged or GFP-tagged ID1 to facilitate detection and localization studies .

For ID1 knockdown:

• siRNA/shRNA approaches: Design RNA interference constructs targeting conserved regions of ID1 mRNA. Validate knockdown efficiency by Western blotting and qRT-PCR.

• CRISPR-Cas9 gene editing: Generate ID1 knockout cell lines for complete loss-of-function studies.

Phenotypic analysis methods following ID1 modulation:

• Cell invasion assays: Evaluate changes in invasive potential using Boyden chamber or 3D matrix invasion assays .

• Mitotic phenotype analysis: Examine centrosome numbers and spindle morphology through immunofluorescence with α-tubulin and centrosomal markers .

• Live cell imaging: Monitor mitotic progression and chromosome segregation in real-time using fluorescently labeled chromosomes or mitotic markers .

• Cell cycle analysis: Assess cell cycle distribution changes using flow cytometry.

• Differentiation assays: Evaluate changes in lineage-specific markers, particularly in stem cell models.

Research has shown that ID1 overexpression induces abnormal mitotic phenotypes including multipolar spindles (26% in NP460hTert-Id1 cells), increased centrosome numbers, and tetraploidization . Conversely, targeting ID1 expression reduces the invasive phenotype of metastatic breast cancer cells both in vitro and in vivo .

What signaling pathways are regulated by or interact with ID1 protein in cancer progression?

ID1 protein is involved in multiple signaling networks that contribute to cancer progression:

• Cell Cycle Regulation Pathway: ID1 disrupts mitotic spindle formation and centrosome regulation by interacting with Aurora A and cdh1, leading to tetraploidization and chromosomal instability . This interaction affects the anaphase-promoting complex/cyclosome (APC/C) activity, which regulates mitotic progression.

• Rb Pathway: ID1 interferes with the retinoblastoma (Rb) regulatory pathway, contributing to loss of cell cycle control. This interference facilitates cellular immortalization and bypassing of senescence checkpoints .

• p16INK4A Suppression: ID1 facilitates immortalization by repressing p16INK4A expression in human fibroblasts, which allows cells to escape cellular senescence and continue proliferating .

• Transcriptional Regulation Networks: As a dominant-negative regulator of basic helix-loop-helix (bHLH) transcription factors, ID1 antagonizes differentiation-specific gene expression programs by forming DNA binding-incompetent heterodimers .

• Developmental Signaling in B Cell Lymphopoiesis: ID1 restrains B cell developmental progression, suggesting its involvement in hematopoietic differentiation pathways .

• Invasion Signaling in Breast Cancer: ID1 acts as a critical regulator of breast cancer progression and invasion, making it a potential molecular target for therapeutic intervention .

Understanding these pathway interactions provides multiple potential points for therapeutic intervention. Experimental approaches to study these pathways include phosphorylation state analysis, protein-protein interaction studies, transcriptional profiling after ID1 modulation, and targeted pathway inhibition combined with ID1 knockdown or overexpression.

How can ID1 antibodies be used to study tumor heterogeneity in patient samples?

ID1 antibodies can serve as valuable tools for investigating tumor heterogeneity through several methodological approaches:

• Multiplex immunohistochemistry (mIHC): Combine ID1 antibody with other cancer biomarkers to simultaneously visualize multiple proteins within the same tissue section. This reveals the spatial relationships between ID1-expressing cells and other tumor subpopulations. Use tyramide signal amplification to enable multiple rounds of staining on the same section.

• Tissue microarray (TMA) analysis: Apply ID1 antibody to TMAs containing multiple samples from different tumor regions to quantitatively assess expression heterogeneity across patients and within individual tumors. This is particularly valuable given the correlation between ID1 expression and tumor grade in breast cancer, where approximately 20% of grade I versus >60% of grade III tumors show strong ID1 staining .

• Single-cell analysis: Utilize ID1 antibody in flow cytometry or mass cytometry (CyTOF) panels to analyze ID1 expression at the single-cell level, enabling identification of distinct cellular subpopulations within heterogeneous tumors.

• Laser capture microdissection with immunostaining: Use ID1 immunostaining to guide microdissection of specific cellular populations for subsequent molecular analysis, including transcriptomics or proteomics.

• Spatial transcriptomics correlation: Correlate ID1 protein expression patterns with spatial transcriptomic data to understand how protein expression relates to transcriptional heterogeneity within the tumor microenvironment.

Implementation guidelines include using validated antibody dilutions (such as those established for immunofluorescence: 5-10 μg/mL) , incorporating appropriate positive and negative controls, and analyzing both cytoplasmic and nuclear staining patterns, as ID1 has been shown to localize to both compartments .

What factors can affect ID1 antibody specificity and how can these be addressed?

Several factors can impact ID1 antibody specificity:

• Cross-reactivity with other ID family members: ID1 shares sequence homology with other ID family proteins (ID2, ID3, ID4). To address this:

  • Use antibodies raised against unique regions of ID1

  • Validate specificity using Western blot analysis on recombinant ID1-4 proteins

  • Confirm results with multiple ID1 antibodies targeting different epitopes

• Post-translational modifications: Phosphorylation or other modifications may affect epitope recognition. Solutions include:

  • Using phosphorylation-state specific antibodies when relevant

  • Treating samples with phosphatases to establish if modification affects detection

  • Employing denaturing conditions in Western blots to expose all epitopes

• Fixation artifacts in immunohistochemistry: Different fixation methods can mask epitopes. Optimize by:

  • Testing multiple fixatives (PFA, methanol, acetone)

  • Implementing appropriate antigen retrieval methods

  • Using fresh frozen sections alongside fixed tissues when possible

• Antibody batch variation: Lot-to-lot variability can affect consistency. Mitigate by:

  • Testing each new lot against a reference standard

  • Purchasing larger quantities of a validated lot when possible

  • Using recombinant antibodies when available for greater consistency

• Non-specific binding: Secondary antibody or primary antibody background can obscure results. Address by:

  • Including isotype controls and secondary-only controls

  • Using more stringent blocking conditions (5% BSA or normal serum)

  • Titrating antibody concentrations to optimize signal-to-noise ratio

• Species cross-reactivity considerations: When working with multiple species, verify:

  • The antibody's validated species reactivity (Human/Mouse ID1 Antibody has been validated for both species)

  • Sequence homology between species at the epitope region

  • Species-specific positive controls in each experiment

How can I address inconsistent results when using ID1 antibody for immunohistochemistry in different tissue types?

When facing inconsistent ID1 immunohistochemistry results across different tissues:

• Optimize tissue-specific fixation protocols:

  • Duration: Adjust fixation time based on tissue density (shorter for soft tissues, longer for dense tissues)

  • Fixative choice: Compare 10% neutral buffered formalin with alternatives like Bouin's solution

  • Sample thickness: Standardize to 3-5 mm thickness for consistent fixative penetration

• Implement tissue-specific antigen retrieval:

  • Heat-induced epitope retrieval (HIER): Test different pH buffers (citrate pH 6.0 vs. EDTA pH 9.0)

  • Enzymatic retrieval: Consider proteinase K or trypsin for certain tissues

  • Duration optimization: Adjust treatment time based on tissue type (typically 10-30 minutes)

• Validate antibody concentration per tissue type:

  • Perform antibody titration series for each tissue type

  • Create a reference table of optimal concentrations for different tissues

  • Consider signal amplification systems for tissues with lower expression

• Account for tissue-specific background:

  • Use tissue-matched blocking reagents (e.g., normal serum from the same species as tissue)

  • Apply hydrogen peroxide treatment to block endogenous peroxidase

  • Employ avidin-biotin blocking for tissues with high biotin content

• Standardize controls:

  • Include known positive tissue controls with each staining batch

  • Use tissue microarrays containing multiple tissue types for direct comparison

  • Implement antibody validation with siRNA knockdown or overexpression controls

• Consider tissue-specific expression patterns:

  • ID1 expression varies by cell type - in breast carcinoma, approximately 80% of ID1-positive cells show cytoplasmic staining

  • In embryonic stem cells vs. neural progenitor cells, differential nuclear localization patterns have been observed

  • Document these patterns to establish tissue-specific reference standards

• Verify with alternative detection methods:

  • Confirm IHC findings with Western blot or RNA expression analysis

  • Use dual IF/IHC approach to verify expression in specific cell populations

  • Apply in situ hybridization to confirm transcript localization

What challenges might arise when measuring ID1 expression in primary patient samples and how can they be overcome?

Measuring ID1 expression in primary patient samples presents several challenges:

How does fixation and sample preparation affect ID1 antibody binding and what are the optimal protocols?

Fixation and sample preparation significantly impact ID1 antibody binding efficacy:

Effects of different fixation methods on ID1 detection:

Optimal sample preparation protocol for ID1 immunodetection:

• For cultured cells (immunofluorescence):

  • Grow cells on coverslips to 70-80% confluence

  • Wash twice with PBS

  • Fix with 4% PFA for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

  • Block with 5% normal serum for 1 hour

  • Incubate with ID1 antibody at 5-10 μg/mL for 3 hours at room temperature

  • Proceed with secondary antibody detection

• For tissue sections (IHC):

  • Fix tissue in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-5 μm thickness

  • Deparaffinize and rehydrate

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes

  • Block endogenous peroxidase with 3% H₂O₂

  • Block with 5% normal serum for 1 hour

  • Incubate with optimized ID1 antibody concentration overnight at 4°C

  • Detect using appropriate secondary detection system

• For Western blotting:

  • Extract proteins using RIPA buffer with protease inhibitors

  • Separate nuclear and cytoplasmic fractions when possible, as ID1 localizes to both compartments

  • Load 20 μg of cytoplasmic extract or 10 μg of nuclear extract per lane

  • Use reducing conditions

  • Transfer to PVDF membrane

  • Block with 5% non-fat milk in TBST

  • Incubate with ID1 antibody at 1:1000 dilution (for Santa Cruz antibody) or 1 μg/mL (for R&D Systems antibody)

  • Detect using HRP-conjugated secondary antibody and ECL

Critical considerations:

• The expected molecular weight of ID1 is approximately 25 kDa in Western blots

• The subcellular localization of ID1 can be both nuclear and cytoplasmic

• Antigen retrieval is critical for formalin-fixed tissues due to cross-linking that may mask the ID1 epitope

How can ID1 antibodies be utilized in studying cancer stem cell populations?

ID1 antibodies can be powerful tools for investigating cancer stem cell (CSC) populations through several methodological approaches:

• Identification and isolation of CSC subpopulations:

  • Combine ID1 antibody with established CSC markers (CD44, CD133, ALDH) in multiparameter flow cytometry

  • Analyze co-expression patterns to identify potential CSC subsets

  • Use fluorescence-activated cell sorting (FACS) with ID1 antibody to isolate ID1-high populations for functional studies

• Lineage tracing and fate mapping:

  • Apply ID1 antibody in tumor tissues after xenografting ID1-expressing cells to track their differential contribution to tumor growth

  • Use inducible ID1 reporter systems combined with antibody validation to monitor dynamic expression changes during differentiation

• Therapeutic resistance studies:

  • Evaluate ID1 expression changes before and after treatment using immunohistochemistry or flow cytometry

  • Correlate ID1 expression with resistance markers and treatment outcomes

  • Apply ID1 antibody to identify surviving cell populations after therapy

• Differentiation potential assessment:

  • Monitor ID1 expression during forced differentiation protocols using time-course immunofluorescence

  • Quantify nuclear-to-cytoplasmic ratio changes of ID1 during differentiation (ID1 localization differs between undifferentiated and differentiated states in embryonic stem cells)

• Niche interaction studies:

  • Use multiplex immunofluorescence with ID1 antibody and microenvironmental markers to examine spatial relationships

  • Analyze ID1 expression in 3D culture systems versus 2D to assess niche-dependent regulation

• Functional validation:

  • Compare tumorigenic potential of ID1-high versus ID1-low populations using limiting dilution assays

  • Apply RNA interference to ID1-expressing stem-like cells and assess phenotypic changes

Implementation requires carefully optimized antibody concentrations (5-10 μg/mL for immunofluorescence) , appropriate positive controls (PC-3 cells) , and consideration of ID1's dual nuclear/cytoplasmic localization patterns, which may vary with stemness state.

What is the role of ID1 in regulating B lymphopoiesis and how can researchers study this process?

ID1 plays a physiological role in restraining B lymphocyte developmental progression, which is crucial for normal immune system development. Researchers can study this process using the following methodological approaches:

• B cell developmental stage analysis:

  • Use flow cytometry with ID1 antibody alongside B cell developmental markers (B220, CD19, IgM, etc.)

  • Quantify ID1 expression at different maturation stages from pro-B to mature B cells

  • Compare wild-type expression patterns with ID1-deficient models to identify stage-specific effects

• In vitro B cell differentiation systems:

  • Establish co-culture systems using stromal cells and hematopoietic progenitors

  • Monitor changes in ID1 expression throughout B cell development using immunofluorescence and flow cytometry

  • Compare differentiation rates between wild-type and ID1-deficient progenitors

• Bone marrow transplantation studies:

  • Transplant wild-type (CD45.1) and ID1-deficient (CD45.2) progenitors to study competitive reconstitution

  • Analyze whether the increased B lymphopoiesis is due to an intrinsic effect of ID1 deficiency on B lineage cells or altered cytokine production

  • Assess if myeloid lineage development is affected by altered ID1 expression

• Transcriptional regulation analysis:

  • Perform ChIP-seq to identify transcription factors regulated by ID1 during B cell development

  • Analyze expression of ID1 target genes in sorted B cell populations

  • Compare transcriptomes of ID1-sufficient and ID1-deficient B cells at different developmental stages

• Mechanistic studies:

  • Investigate whether ID1's regulation of B cell development occurs through its canonical function as an inhibitor of bHLH transcription factors

  • Assess interactions between ID1 and key B cell transcription factors (E2A, EBF, Pax5)

  • Examine how ID1 expression is regulated by external signals (cytokines, stromal factors)

Research has demonstrated that ID1 deficiency leads to increased B lymphopoiesis without affecting myeloid lineage cells, suggesting a specific role in B cell development . The experimental approaches outlined above can help elucidate the precise mechanisms through which ID1 restrains B cell developmental progression and maintains appropriate immune system homeostasis.

How might ID1 antibodies be used in developing targeted cancer therapies?

ID1 antibodies can contribute to targeted cancer therapy development through several strategic approaches:

• Therapeutic target validation:

  • Use ID1 antibodies to validate expression patterns across multiple cancer types and correlate with clinical outcomes

  • Employ tissue microarrays to screen large patient cohorts for ID1 expression (building on findings that >60% of grade III breast carcinomas show strong ID1 expression)

  • Identify cancer subtypes most likely to respond to ID1-targeted therapy

• Development of antibody-drug conjugates (ADCs):

  • Modify ID1 antibodies to carry cytotoxic payloads selectively to ID1-expressing cancer cells

  • Optimize internalization kinetics through epitope selection and antibody engineering

  • Test efficacy in patient-derived xenograft models expressing varying levels of ID1

• Companion diagnostic development:

  • Standardize ID1 immunohistochemistry protocols for patient stratification

  • Develop quantitative scoring systems correlating expression levels with therapeutic response

  • Create multiplexed assays combining ID1 with other biomarkers to improve patient selection

• Mechanism-based combination therapies:

  • Use ID1 antibodies to monitor expression changes during treatment with various agents

  • Identify drugs that downregulate ID1 expression for potential synergistic combinations

  • Study resistance mechanisms by analyzing ID1 expression in treatment-resistant populations

• Functional blocking antibodies:

  • Develop antibodies targeting extracellular ID1 (if present) or delivery systems for intracellular targeting

  • Test ability to disrupt ID1's interactions with binding partners (Aurora A, cdh1)

  • Evaluate effects on cancer cell invasion and abnormal mitotic phenotypes

• Immunotherapy approaches:

  • Investigate ID1 as a tumor-associated antigen for vaccine development

  • Use ID1 antibodies to identify potential epitopes for T-cell based immunotherapies

  • Develop CAR-T approaches targeting ID1-expressing cancer cells if cell-surface presentation is confirmed

Research has demonstrated that targeting ID1 reduces human breast cancer cell invasion in vitro and in vivo , making it a promising therapeutic target. As ID1 is overexpressed in multiple human cancers including nasopharyngeal carcinoma and breast cancer , antibody-based approaches to detection, targeting, and monitoring could significantly advance personalized cancer therapy development.

What potential applications exist for ID1 antibodies in regenerative medicine and stem cell research?

ID1 antibodies offer valuable applications in regenerative medicine and stem cell research:

• Stem cell identity and pluripotency assessment:

  • Use ID1 antibodies to track expression in embryonic stem cells during maintenance and differentiation

  • Monitor ID1 localization changes between undifferentiated (higher nuclear expression) and differentiated states (altered localization pattern)

  • Develop quality control metrics for stem cell preparations based on ID1 expression patterns

• Lineage specification monitoring:

  • Apply ID1 antibodies in time-course studies during directed differentiation

  • Quantify expression changes as cells transition between states

  • Correlate ID1 levels with expression of lineage-specific transcription factors

• Tissue regeneration assessment:

  • Analyze ID1 expression in regenerating tissues using immunohistochemistry

  • Compare expression patterns between successful and failed regeneration attempts

  • Investigate ID1's role in maintaining progenitor populations during healing

• iPSC reprogramming optimization:

  • Monitor ID1 expression during reprogramming process

  • Determine if ID1 modulation can enhance reprogramming efficiency

  • Investigate ID1's interaction with pluripotency factors

• Organoid development and characterization:

  • Use ID1 antibodies to identify stem/progenitor populations within developing organoids

  • Track spatial organization of ID1-expressing cells during self-organization

  • Compare ID1 expression patterns between organoids and native tissues

• Cell therapy product validation:

  • Develop release criteria incorporating ID1 expression for cell therapy products

  • Use ID1 antibodies in quality control processes for therapeutic cell preparations

  • Monitor ID1 expression stability during manufacturing and storage

• Aging and senescence studies:

  • Investigate changes in ID1 expression with cellular aging

  • Use ID1 antibodies to study the relationship between ID1 suppression and cellular senescence

  • Explore whether restoring ID1 expression can reverse age-related stem cell dysfunction

Research has demonstrated that ID1 is expressed in undifferentiated human embryonic stem cells and shows altered expression upon differentiation into neural progenitor cells . Additionally, ID1 has been shown to suppress cellular senescence and facilitate immortalization , suggesting its importance in maintaining stem cell properties. These findings provide a foundation for developing ID1 antibody-based applications in regenerative medicine and stem cell research.

How can researchers effectively combine ID1 antibodies with other molecular tools for comprehensive pathway analysis?

Researchers can implement several methodological approaches to combine ID1 antibodies with complementary molecular tools for comprehensive pathway analysis:

• Multiplexed protein analysis:

  • Combine ID1 antibodies with antibodies against pathway components in multiplex immunofluorescence assays

  • Use cyclic immunofluorescence (CycIF) to sequentially stain the same sample with up to 30+ antibodies

  • Implement mass cytometry (CyTOF) with metal-conjugated ID1 antibodies alongside pathway markers for high-dimensional single-cell protein profiling

• Multi-omics integration:

  • Correlate ID1 protein expression (detected by antibodies) with transcriptomic data from the same samples

  • Use cell sorting based on ID1 antibody staining followed by RNA-seq or proteomics

  • Apply spatial transcriptomics alongside ID1 immunohistochemistry on sequential sections to map expression patterns

• Live-cell imaging combined with fixed endpoint analysis:

  • Track cells using live fluorescent reporters for pathway activation

  • Fix at critical timepoints for ID1 antibody staining

  • Correlate dynamic signaling behaviors with ID1 expression patterns

• Pathway perturbation coupled with ID1 detection:

  • Apply small molecule inhibitors of relevant pathways (Rb pathway, Aurora kinases)

  • Monitor effects on ID1 expression and localization using antibody-based detection

  • Use inducible expression/knockout systems for pathway components while tracking ID1

• Protein-protein interaction analysis:

  • Combine ID1 antibodies with proximity ligation assays to visualize interactions with binding partners

  • Perform co-immunoprecipitation with ID1 antibodies followed by mass spectrometry to identify novel interactors

  • Use FRET/FLIM microscopy with fluorophore-conjugated antibodies to study protein interactions in situ

• Chromatin association studies:

  • Apply ChIP-seq using ID1 antibodies to identify genomic binding sites

  • Combine with CUT&RUN or CUT&Tag for higher resolution

  • Correlate binding patterns with transcriptional outcomes using RNA-seq

• Combinatorial functional genomics:

  • Perform CRISPR screens in cells with different ID1 expression levels

  • Use ID1 antibodies to validate hits and study pathway connections

  • Implement synthetic lethality screens to identify targetable dependencies in ID1-overexpressing cells

Practical implementation requires careful antibody validation for each application, appropriate controls (including positive controls like PC-3 cells and negative controls like Daudi cells) , and consideration of ID1's dual nuclear/cytoplasmic localization which may have distinct functional implications .